Asset Details
Do you wish to reserve the book?
Serum exosomal miR‐378 upregulation is associated with poor prognosis in non–small‐cell lung cancer patients
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Serum exosomal miR‐378 upregulation is associated with poor prognosis in non–small‐cell lung cancer patients
Do you wish to request the book?
Serum exosomal miR‐378 upregulation is associated with poor prognosis in non–small‐cell lung cancer patients
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Serum exosomal miR‐378 upregulation is associated with poor prognosis in non–small‐cell lung cancer patients
2020
Overview
Background Deregulated circulating microRNAs (miRNAs) are potential biomarkers for the early detection and prognosis prediction of non–small‐cell lung cancer (NSCLC). The aim of the present study was to investigate the expression pattern of serum exosomal miR‐378 in NSCLC and its correlation with clinical variables. Methods Quantitative reverse transcription‐polymerase chain reaction (qRT‐PCR) was performed to detect serum exosomal miR‐378 levels in 103 patients with NSCLC and 60 control subjects. Results Our results showed that serum exosomal miR‐378 was significantly overexpressed in NSCLC patients, and serum exosomal miR‐378 upregulation was clearly associated with positive lymph node metastasis and advanced TNM stage. In addition, receiver operating characteristic (ROC) analysis demonstrated that combination of serum exosomal miR‐378 expression and carcinoembryonic antigen (CEA) had a high discriminating power to differentiate NSCLC subjects from controls. Moreover, serum exosomal miR‐378 levels in 73 NSCLC cases were significantly decreased after radiotherapy and could be used as an indicator of radiotherapeutic response in NSCLC. Furthermore, survival analyses revealed that patients with higher serum exosomal miR‐378 expression had poor overall survival. Multivariate analysis showed that serum exosomal miR‐378 expression was independently associated with overall survival. Conclusions Collectively, serum exosomal miR‐378 has strong potential as a promising non‐invasive biomarker for screening and monitoring NSCLC.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc
Subject
